The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials

The extent of the benefit of bevacizumab combined with chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) is still unclear. We performed this meta-analysis to compare the efficacy of bevacizumab with other commonly used targeted drugs for different patients with advanced NS...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2013-04, Vol.8 (4), p.e62038-e62038
Hauptverfasser:	Cui, Jianlan, Cai, Xueya, Zhu, Min, Liu, Tianshu, Zhao, Naiqing
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis inhibitors Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Clinical trials Comparative analysis Disease-Free Survival Drug therapy Drugs Effectiveness Evidence-based medicine Humans Immunotherapy Laboratories Lung cancer Lung carcinoma Lung diseases Lung Neoplasms - drug therapy Medical research Medicine Meta-analysis Metastasis Monoclonal antibodies Non-small cell lung cancer Non-small cell lung carcinoma Oncology Patients Public health Randomization Randomized Controlled Trials as Topic Response rates Small cell lung carcinoma Studies Survival Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!